(Reuters) - The Food and Drug Administration usually follows panel
recommendations. A final decision is expected by July 26.
Members of the FDA advisory panel said they had too many
concerns about potential side effects to urge U.S. approval.
Agency reviewers said the drug may increase the chances of
suicidal thoughts, depression and other problems.
Read more at Reuters.com Government Filings News
recommendations. A final decision is expected by July 26.
Members of the FDA advisory panel said they had too many
concerns about potential side effects to urge U.S. approval.
Agency reviewers said the drug may increase the chances of
suicidal thoughts, depression and other problems.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment